Zymeworks Inc. has filed to raise $175 million in a public offering that President and CEO Ali Tehrani told BioWorld will fund his team's "very ambitious plans" for two pivotal phase II/III trials for lead candidate ZW-25 in 2020 and a ramping-up of their study of a second candidate, ZW-49. "We did have the money," but with the additional funds, preparations will move much faster, he said.